Spots Global Cancer Trial Database for Managed Access Programs for LDK378, Ceritinib

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Managed Access Programs for LDK378, Ceritinib

Official Title: Managed Access Programs for LDK378, Ceritinib

Study ID: NCT05100134

Conditions

Anaplastic Lymphoma Kinase (ALK)- Positive Tumors

Non-small Cell Lung Cancer (NSCLC)

Interventions

ceritinib

Study Description

Brief Summary: The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.

Detailed Description: CLDK378A2401 - No longer available - Managed Access Program (MAP) to provide access to Ceritinib, for ALK Positive Tumors. CLDK378A2402 - No longer available - An open-label, multi-center, Expanded Treatment Protocol (ETP) of oral LDK378 in adult patients with non-small cell lung cancer (NSCLC) characterized by ALK positivity. CLDK378A2003M - Available - Managed Access Program (MAP) Cohort Treatment Plan CLDK378A2003M to provide access to LDK378 (ceritinib), for ALK-Positive Tumor Pediatric Patients.